Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8446917 | 0.85 | MEN1 (0.39) | NAMPT | |
| SCHEMBL6397227 | 0.81 | MAOA (0.49) | NAMPTPDK4 | |
| SCHEMBL6397236 | 0.81 | MAOA (0.49) | NAMPTPDK4 | |
| SCHEMBL8445301 | 0.80 | CCNT1 (0.38) | NAMPTKITWNT3A | |
| SCHEMBL7504576 | 0.79 | NAMPT (0.48) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL7126216 | 0.75 | NAMPT (0.49) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL7125301 | 0.75 | NAMPT (0.49) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL8451797 | 0.75 | MAPKAPK2 (0.39) | NAMPTBRD4 | |
| SCHEMBL9930581 | 0.73 | NAMPT (0.44) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL10063627 | 0.73 | HRH3 (0.37) | NAMPTJAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | NAMPT 1769/4885PDK4 887/4885CDK7 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.